Cassava Sciences Inc

NASDAQ:SAVAUnited States

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Contact Information

Headquarters

6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731

Phone

512-501-2444

Fax

512-614-0414

Executives

Chairman of the Board, President, Chief Executive Officer

Remi Barbier

Chief Financial Officer

Eric Schoen

Senior Vice President, General Counsel

R. Christopher Cook

Chief Medical Officer

James Kupiec

Lead Independent Director

Sanford Robertson